SCHEMBL158990

SCHEMBL158990

N=C(N)NCCC[C@H](NC(=O)c1ccccc1)C(N)=O

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PADI1 Q9ULC6 6/20 0.60
PADI4 Q9UM07 6/20 0.60
PADI2 Q9Y2J8 4/20 0.60
PADI3 Q9ULW8 4/20 0.60
PDE4A P27815 3/20 0.60
PDE4B Q07343 2/20 0.60
PDE4C Q08493 2/20 0.60
PDE4D Q08499 2/20 0.60
PADI6 Q6TGC4 1/20 0.60
HPGDS O60760 3/20 0.46
GRIN1 Q05586 2/20 0.46
GRIN2A Q12879 2/20 0.46
KISS1R Q969F8 1/20 0.45
ROCK2 O75116 1/20 0.44
MMP12 P39900 1/20 0.44
F10 P00742 1/20 0.44
C3AR1 Q16581 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10946109 1.00 PADI1 (0.60) PADI1PADI4PADI2PADI3PDE4A
Hydrochloric Acid SCHEMBL29401072 0.97 PADI1 (0.58) PADI1PADI4PADI2PADI3PDE4A
SCHEMBL7925397 0.92 C3AR1 (0.52) PADI1PADI4PADI2PADI3PDE4A
SCHEMBL188589 0.92 C3AR1 (0.52) PADI1PADI4PADI2PADI3PDE4A
SCHEMBL188590 0.92 C3AR1 (0.52) PADI1PADI4PADI2PADI3PDE4A
SCHEMBL10652468 0.88 GRIN1 (0.48) PADI1PADI4PADI2PADI3PDE4A
Naphthalene SCHEMBL28216957 0.88 C3AR1 (0.49) PADI1PADI4PADI2PADI3PDE4A
SCHEMBL1979577 0.88 PADI4 (0.63) PADI1PADI4PADI2PADI3PDE4A
SCHEMBL20138329 0.88 PADI4 (0.63) PADI1PADI4PADI2PADI3PDE4A
SCHEMBL1979695 0.87 PADI4 (0.62) PADI1PADI4PADI2PADI3PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160333081-A1 TREATMENT OF SEPSIS AND SEPTIC SHOCK THE GENERAL HOSPITAL CORPORATION (US) 2016-11-17 US claimed
US-9205069-B2 Inhibitors of anaphase promoting complex activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2015-12-08 US claimed
WO-2015116896-A1 TREATMENT OF SEPSIS AND SEPTIC SHOCK THE GENERAL HOSPITAL CORPORATION (US) 2015-08-06 WO claimed
US-20120115948-A1 INHIBITORS OF ANAPHASE PROMOTING COMPLEX ACTIVITY PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2012-05-10 US claimed
WO-2010102281-A2 INHIBITORS OF ANAPHASE PROMOTING COMPLEX ACTIVITY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2010-09-10 WO claimed
EP-1585485-A2 COMPOSITIONS FOR THE REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2005-10-19 EP claimed
WO-2004064749-A2 COMPOSITIONS FOR THE REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2004-08-05 WO claimed
US-20040141935-A1 Reduction of hair growth GILLETTE COMPANY, THE 2004-07-22 US claimed
EP-0754023-B1 INHIBITION OF HAIR GROWTH HANDELMAN JOSEPH H (US) 1999-05-26 EP claimed
EP-0754023-A1 INHIBITION OF HAIR GROWTH HANDELMAN, Joseph H. (US) 1997-01-22 EP claimed
US-5468476-A Enzyme inhibitor GILLETTE CO., THE 1995-11-21 US claimed
WO-1995024884-A1 INHIBITION OF HAIR GROWTH HANDELMAN, JOSEPH, H. (US) 1995-09-21 WO claimed
EP-4620463-A1 ACTIVE AGENT FOR USE IN HAIR GROWTH REGULATION CUTANEON - Skin & Hair Innovations GmbH (DE) 2025-09-24 EP disclosed
US-20230321122-A1 ACTIVE AGENT MODULATING THE ACTIVITY OF AN ION CHANNEL FOR USE IN HAIR GROWTH REGULATION CUTANEON SKIN & HAIR INNOVATIONS GMBH (DE) 2023-10-12 US disclosed
EP-3766545-B1 ACTIVE AGENT FOR USE IN HAIR GROWTH REGULATION CUTANEON SKIN & HAIR INNOVATIONS GMBH (DE) 2023-08-16 EP disclosed
US-20220168206-A1 ACTIVE AGENT FOR USE IN HAIR GROWTH REGULATION CUTANEON - SKIN & HAIR INNOVATIONS GMBH (DE) 2022-06-02 US disclosed
US-5468476-A Enzyme inhibitor GILLETTE CO., THE 1995-11-21 US disclosed
WO-1995024884-A1 INHIBITION OF HAIR GROWTH HANDELMAN, JOSEPH, H. (US) 1995-09-21 WO disclosed
US-4521254-A Cleaning contact lenses with solution of bromelain and carboxypeptidase ANDERSON SCIENTIFIC INC. 1985-06-04 US disclosed
US-4086136-A Process for producing a peptide using a serine or thiol proteinase (ZAIDANHOJIN) SAGAMI CHEMICAL RESEARCH CENTER (JA) 1978-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160333081-A1 TREATMENT OF SEPSIS AND SEPTIC SHOCK H1-3, EHMT2, H1-4 PADI1 20/4885PADI4 9/4885PADI2 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.